4931431F19Rik Activators
Chemical activators of ubiquilin 5 play a role in modulating its activity by interacting with the pathways that govern its functional state. Lithium Chloride, for instance, is known to engage with glycogen synthase kinase 3 beta (GSK-3β), an enzyme that when inhibited, allows ubiquilin 5 to elude phosphorylation-dependent inactivation. This preservation of ubiquilin 5's active form is vital for its ability to facilitate the degradation of misfolded proteins via the proteasome. Similarly, other GSK-3β inhibitors, including SB216763, Indirubin-3'-monoxime, BIO, AR-A014418, Tideglusib, CHIR99021, and Valproic Acid, function to sustain ubiquilin 5 in an active state by preventing the inhibitory phosphorylation that would otherwise impair its role in protein quality control. This mechanism ensures that ubiquilin 5 remains capable of interacting effectively with the proteasome system to carry out its essential function in regulating protein degradation.
Further expanding the list of chemical activators, TDZD-8, Alsterpaullone, H-89, and Kenpaullone also contribute to the activation of ubiquilin 5. TDZD-8, as a non-ATP competitive inhibitor of GSK-3β, ensures that ubiquilin 5 does not undergo the phosphorylation which typically curtails its activity. Alsterpaullone and Kenpaullone, by inhibiting GSK-3β, prevent the phosphorylation of ubiquilin 5, enabling it to persist in an active state that is essential for the maintenance of cellular proteostasis. H-89, while being a well-known protein kinase A inhibitor, has also been shown to inhibit GSK-3β, thereby indirectly supporting the activation state of ubiquilin 5. Collectively, these chemicals maintain the dephosphorylated, active form of ubiquilin 5, ensuring its continued participation in the degradation of proteins deemed aberrant.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium ions can activate glycogen synthase kinase 3 beta (GSK-3β) inhibitors, which in turn can enhance the activity of ubiquilin 5 by preventing its phosphorylation-dependent inactivation, allowing ubiquilin 5 to facilitate the degradation of misfolded proteins via the proteasome. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 acts as a potent and selective inhibitor of GSK-3β, which may lead to the activation of ubiquilin 5 by preventing GSK-3β-mediated inhibitory phosphorylation, thereby promoting its protein quality control functions. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a known GSK-3β inhibitor and could enhance ubiquilin 5 activity by preventing its inactivation through phosphorylation, maintaining its role in protein degradation pathways. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
6-Bromoindirubin-3'-oxime (BIO) inhibits GSK-3β, potentially leading to the activation of ubiquilin 5 by averting the phosphorylation that would otherwise inhibit its proteostasis-related activities. | ||||||
GSK-3β Inhibitor VIII | 487021-52-3 | sc-202636 sc-202636A | 5 mg 10 mg | $134.00 $150.00 | 5 | |
As a GSK-3β inhibitor, AR-A014418 may activate ubiquilin 5 by reducing phosphorylation-mediated inactivation, enhancing its ability to interact with the proteasome for protein clearance. | ||||||
Tideglusib | 865854-05-3 | sc-507358 | 10 mg | $77.00 | ||
Tideglusib inhibits GSK-3β, which could result in the activation of ubiquilin 5 by sustaining its active form that participates in the regulation of protein degradation mechanisms. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
This GSK-3β inhibitor can activate ubiquilin 5 by allowing it to maintain its active role in proteasomal degradation, by preventing inhibitory phosphorylation processes. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, while primarily known for other targets, can also inhibit GSK-3β and might thereby activate ubiquilin 5, ensuring its functional role in protein quality control is sustained. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone serves as a GSK-3β inhibitor that could activate ubiquilin 5 by avoiding the phosphorylation that typically dampens its activity in protein turnover processes. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is another GSK-3β inhibitor that can activate ubiquilin 5 by preventing its inactivation through phosphorylation, thereby promoting its role in proteostasis. | ||||||